Your browser doesn't support javascript.
loading
Maintenance lenalidomide could be most relevant after first-line therapy.
Chang, Julie E.
Affiliation
  • Chang JE; Department of Medicine, Section of Hematology & Oncology, University of Wisconsin School of Medicine and Public Health Madison, WI 53705-2275, USA. Electronic address: jc2@medicine.wisc.edu.
Lancet Haematol ; 4(11): e502-e503, 2017 11.
Article in En | MEDLINE | ID: mdl-28958468
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Multiple Myeloma Limits: Humans Language: En Journal: Lancet Haematol Year: 2017 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Multiple Myeloma Limits: Humans Language: En Journal: Lancet Haematol Year: 2017 Document type: Article